Lilly, AI biotech Profluent ink $2.25B pact in search of genetic 'holy grail' (www.biospace.com)

Eli Lilly has entered a significant $2.25 billion deal with Profluent Bio, an AI-driven biotech firm, aimed at advancing DNA editing technologies to address genetic diseases with high unmet needs. This collaboration will leverage Profluent's AI capabilities to design site-specific recombinases—enzymes essential for targeted DNA modification—which are expected to enable the insertion of larger DNA fragments than current methods allow. This approach, referred to as kilobase-scale DNA editing, aims to tackle the complexities of genetic diseases that result from multiple mutations, thus paving the way for more effective therapies. The partnership marks a pivotal moment in the AI/ML community, highlighting the growing integration of artificial intelligence in biopharmaceutical research. Lilly's ongoing commitment to AI-driven initiatives is further reinforced by its recent collaborations and technological investments, such as developing a supercomputer with NVIDIA for drug discovery. The prospect of creating designer recombinases through AI not only raises the bar for genetic medicine but also reflects the potential of AI to unlock therapeutic solutions previously deemed impossible. As both companies pursue this ambitious goal, the deal underscores the transformative power of AI in enhancing our understanding and treatment of complex genetic conditions.